ID: ALA4879073

Max Phase: Preclinical

Molecular Formula: C34H43N7OS

Molecular Weight: 597.83

Molecule Type: Unknown

Representations

Canonical SMILES:  CC(C)c1cccc(C(C)C)c1NC(=O)N1CCN(c2ncnc3sc(-c4ccc(N5CCN(C)CC5)cc4)cc23)CC1

Standard InChI:  InChI=1S/C34H43N7OS/c1-23(2)27-7-6-8-28(24(3)4)31(27)37-34(42)41-19-17-40(18-20-41)32-29-21-30(43-33(29)36-22-35-32)25-9-11-26(12-10-25)39-15-13-38(5)14-16-39/h6-12,21-24H,13-20H2,1-5H3,(H,37,42)

Standard InChI Key:  YVOMUIVDDXSSPB-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 597.83

Molecular Weight (Monoisotopic): 597.3250

AlogP: 6.71

#Rotatable Bonds: 6

Polar Surface Area: 67.84

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 13.50

CX Basic pKa: 7.84

CX LogP: 7.07

CX LogD: 6.49

Aromatic Rings: 4

Heavy Atoms: 43

QED Weighted: 0.27

Np Likeness Score: -1.57

References

1. Li Y, Yang G, Zhang J, Tang P, Yang C, Wang G, Chen J, Liu J, Zhang L, Ouyang L..  (2021)  Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer.,  64  (16.0): [PMID:34351741] [10.1021/acs.jmedchem.1c00678]

Source

Source(1):

• Scientific Literature